Regular Use Of Antithrombotic Drug Increases The Risk Of Nonbiliary Acute Pancreatitis: A Prospective Cohort Study

Chen-yang Wei[1,2†], Ning-ning Mi[1,2,3†], Jin-yu Zhao[1,2], Peng-fei Li[1,2], Zheng-ping An[1,2], Sheng Chen[1,2], Yan-yan Lin[1,2], Ping Yue[1,2], Jin-qiu Yuan[3*] and Wen-bo Meng[1,2*]

Affiliations

[1]*The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, China.*

[2]*Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.*

[3]*Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China.*

*** Corresponding Authors:**

Professor Wenbo Meng, Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, 730000, Gansu, China;

Email: mengwb@lzu.edu.cn.

Professor Jinqiu Yuan, Clinical Research Center, Big Data Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, 518107, Guangdong, China;

Email: yuanjq5@mail.sysu.edu.cn.

†: These authors have contributed equally to this work and share first authorship.

Keywords: Antithrombotic; Acute pancreatitis; Type 2 diabetes mellitus; Hyperlipidemia; Cohort study.

ABSTRACT

Background

Antithrombotic drugs were widely used for cardiovascular disease prevention, but their association with nonbiliary acute pancreatitis remains unclear.

Aim

This study aimed to investigate the association between regular antithrombotic drug use and the risk of nonbiliary pancreatitis in the UK Biobank.

Methods

This prospective cohort study included 431,754 participants from the UK Biobank. Incident nonbiliary acute pancreatitis was identified through links to primary healthcare and hospitalization data. The Cox proportional hazards model estimated the relationship between antithrombotic drug use and nonbiliary acute pancreatitis risk.

Results

During a median follow-up period of 13.73 years, 2,189 nonbiliary acute pancreatitis cases were recorded. Antithrombotic users had a 31% higher risk of nonbiliary acute pancreatitis than non-users (HR = 1.31, 95% CI: 1.08 - 1.61, p = 0.007). Risk varied by specific agent: clopidogrel was associated with a 53% increased risk (HR = 1.53, 95% CI:

1.08 - 2.16, p = 0.016). For warfarin, the overall association was not statistically significant (HR = 1.32, 95% CI: 0.97 - 1.80, p = 0.076); however, subgroup analysis indicated that the association was confined to non-diabetic individuals (P-interaction = 0.015; HR = 1.64, 95% CI: 1.15 - 2.35, p = 0.007). No significant associations were observed for low-dose aspirin and dipyridamole. These results remained robust in sensitivity analyses, including propensity score matching analysis and lagging the exposure for one year.

Conclusions:

Regular use of antithrombotic drugs, especially clopidogrel, was associated with an increased risk of nonbiliary acute pancreatitis. The risk associated with warfarin was specific to non-diabetic individuals.

Introduction

Acute pancreatitis is an inflammatory disorder of the pancreas associated with substantial morbidity and mortality, imposing a substantial burden on healthcare systems worldwide[1]. In severe cases, it can progress to systemic inflammation and multiple organ failure, with a mortality rate as high as 85%[2]. The etiological spectrum of AP exhibits significant geographical variation: in Western countries, biliary disease is the leading cause, followed by alcoholic and hypertriglyceridemia-induced pancreatitis. However, in Asian countries, including China, hypertriglyceridemia accounts for a substantially higher proportion of cases[3]. The rapidly increasing prevalence of hypertriglyceridemia-related AP has established it as a pressing global health concern[4,5].

Besides the traditional causes, medications are also recognized as potential inducers of AP[6,7]. Antithrombotic agents have drawn particular attention due to their widespread use in patients with cardiovascular diseases[8,9]. However, evidence regarding the association between these drugs and the risk of AP remains notably controversial, with no consensus reached to date. Evidence from animal models suggests a potential protective effect: pretreatment with low-dose warfarin can alleviate ischemia/reperfusion-induced pancreatic injury via this mechanism[10,11]. A recent large-scale clinical study also found that among patients with established AP, the use of low-dose aspirin was associated

with lower mortality and reduced risk of complications[12]. In contrast, other observational studies have reported an elevated risk[13–16]. This conflicting body of evidence creates a dilemma for clinicians managing the substantial population of patients with cardiovascular diseases who require long-term antithrombotic therapy, making it challenging to assess their potential AP risk.

Given these conflicting findings, a rigorous investigation is warranted to clarify the relationship between antithrombotic medication use and the risk of acute pancreatitis (AP). Should these drugs be confirmed as a risk factor, their cardiovascular benefits must be rigorously weighed against the AP risk in clinical decision-making, necessitating heightened clinical vigilance among prescribers. Conversely, evidence of a protective effect would justify further research into mechanisms. To address this knowledge gap, we conducted a prospective analysis of this association within a large cohort of 431,754 individuals.

Methods

Study Population

The study population was derived from the UK Biobank (UKB), a large prospective cohort comprising over 500,000 participants aged 37-73 years. The cohort was established between 2006 and 2010 across 22 assessment centers in England, Wales, and

Scotland. Participants are followed up with regularly for data updates. At recruitment, all individuals completed a baseline questionnaire and underwent assessments that included physical measurements, as well as detailed information on lifestyle and medication use. Further details regarding the UK Biobank cohort have been published elsewhere[17]. Participants with baseline diagnoses of cancer, gallstone disease, or acute pancreatitis were excluded. To prevent gallstone disease from confounding study results, participants who developed acute pancreatitis during follow-up but had previously been diagnosed with gallstone disease were further excluded. Participants lacking follow-up data were also excluded. The final analytical cohort consisted of 431,754 participants (Supplementary Figure 1). All diagnoses were based on International Classification of Diseases-10 (ICD-10) diagnostic criteria.

Exposure assessment

The primary exposure in this study was defined as regular use of antithrombotic drugs at baseline, including anticoagulants and antiplatelet drugs. Specific medications considered were warfarin, low-dose aspirin, clopidogrel, and dipyridamole. At baseline, regular use of antithrombotic drugs was first assessed from participants using a touchscreen questionnaire and then confirmed during verbal interviews with trained staff. In the touchscreen questionnaire, participants were asked, “Do you regularly take any other prescription medications?” “Regular use” of prescription medications was defined as taking them on a long-term and scheduled basis, whether daily, weekly, or monthly

(e.g., depot injections), as reported during the verbal interview. Short-term medications, such as antibiotic courses, were excluded. If the participant selected “Yes” or “Do not know,” the interviewer would ask: “In the touchscreen, you said you are taking regular prescription medications. Can you now tell me what these are?” Information on the use of antithrombotic drugs was recorded using a coded list. The recorded types of antithrombotic drugs mainly included warfarin, low-molecular-weight heparin, low-dose aspirin, clopidogrel, and dipyridamole. Information about doses and duration of antithrombotic agents was not collected. Detailed questions regarding the use of antithrombotic agents can be found on the UK Biobank website.

Outcome ascertainment

Incident cases of acute pancreatitis (AP) were identified from hospital records linked to the Health and Social Care Information Centre (England and Wales) and the National Health Service Central Register (Scotland), using the International Classification of Diseases (ICD-10) code K85. From these AP cases, nonbiliary acute pancreatitis was confirmed by excluding those with a concomitant or prior diagnosis of gallstone disease.

Assessment of Covariates

At enrollment, information on covariates was collected through a touchscreen questionnaire and face-to-face interviews, covering socio-demographic characteristics, anthropometric measurements, lifestyle factors, medical history, and medication use.

Specifically, the data included: (1) socio-demographic factors: age, sex, ethnicity and socioeconomic status (measured using the Index of Multiple Deprivation, IMD, directly obtained from the UK Biobank); (2) anthropometric data: height and weight, with body mass index (BMI) calculated as kg/m^2; (3) lifestyle factors: smoking status, alcohol intake, physical activity (assessed using the short-form International Physical Activity Questionnaire, IPAQ), and healthy diet (defined according to American Heart Association guidelines; Supplementary Table 2); (4) medical history: type 2 diabetes, hypertension, hyperlipidemia, and cardiovascular disease; (5) medication use: nonsteroidal anti-inflammatory drugs (NSAIDs), hypolipidemic drugs, multivitamin and mineral supplements.

Statistical Analysis

Baseline characteristics are presented as means (standard deviation, SD) for continuous variables and as counts (percentages) for categorical variables. Person-years of follow-up were calculated from the date of assessment for each participant until the first diagnosis of acute pancreatitis, death, or the end of follow-up (May 31, 2022), whichever came first.

Cumulative incidence curves for nonbiliary acute pancreatitis were generated to compare non-users with users of antithrombotic drugs, including anticoagulants, antiplatelet agents, and specific medications. A crude model was first constructed to

examine the association between antithrombotic use and the risk of nonbiliary acute pancreatitis. Three adjusted models were then established: Model 1 adjusted for age, gender, ethnicity, and IMD; Model 2 further adjusted for BMI, smoking, alcohol intake, physical activity, and healthy diet; Model 3 additionally adjusted for type 2 diabetes, hypertension, hyperlipidemia, NSAID use, hypolipidemic drugs, multivitamin use, and mineral supplement intake. The proportional hazards assumption was verified using Schoenfeld residuals for all models, with no violations detected.

Subgroup analyses were conducted according to pharmacological class (anticoagulants or antiplatelet agents) and by individual drugs (warfarin, aspirin, clopidogrel, and dipyridamole). Results from the most fully adjusted model (Model 3) are reported as the primary findings in this study.

We evaluated the potential moderating effects of age, sex, BMI, smoking status, alcohol intake, physical activity, healthy diet, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, hypolipidemic drug intake, multivitamin and mineral supplement use, using stratified analysis and interaction testing with a likelihood ratio test in subgroup analyses. Given that type 2 diabetes and hyperlipidemia suggested potential effect modification in the overall analysis, we also tested their interaction effects in the aforementioned stratified medication analyses.

To evaluate the robustness of our findings, we performed several sensitivity analyses:

(1) further adjustment for history of cardiovascular diseases in Model 3 (as Model 4); (2) exclusion of participants who developed the outcome within the first year of follow-up to minimize reverse causality; and (3) a propensity score matching (PSM) analysis to evaluate the effect of antithrombotic medication on nonbiliary acute pancreatitis.

All analyses were conducted using R version 4.5.1. A two-tailed P value < 0.05 was considered statistically significant.

Results

Baseline Characteristics of Participants

Table 1 presents the baseline characteristics of the study participants stratified by antithrombotic medication use. The study included 431,754 participants, of whom 11,140 were antithrombotic medication users. Among the users, 4,452 used anticoagulants only, 6,610 used antiplatelet agents only, and 78 used both antiplatelet agents and anticoagulants. In terms of specific medications, 4,397 used warfarin, 2,514 used low-dose aspirin, 950 used dipyridamole, 2,818 used clopidogrel, and 93 used both aspirin and clopidogrel. Antithrombotic medication users were more likely to be older, male, smokers, alcohol consumers, and have a higher prevalence of comorbidities, including type 2 diabetes, hypertension, and hyperlipidemia.

Antithrombotic Drugs Use and the Risk of Nonbiliary Acute Pancreatitis

During a median follow-up of 13.73 years, 2,189 new cases of nonbiliary acute pancreatitis were recorded, including 109 cases in the antithrombotic drug user group and 2,080 cases in the non-user group. Compared with non-users, a higher cumulative incidence of acute pancreatitis was observed in users of antithrombotic drugs, particularly among users of anticoagulants and clopidogrel (Figure 1a,b and c).

In the crude model, the use of antithrombotic drugs was associated with a 74% increased risk of nonbiliary acute pancreatitis (HR 1.74, 95% CI 1.44-2.12, $p < 0.001$). After adjusting for age, sex, ethnicity, and IMD (Model 1), the HR was 1.66 (95% CI, 1.37-2.02; $p < 0.001$). The association attenuated somewhat but remained significant after further adjustment for lifestyle factors (Model 2) (HR, 1.44; 95% CI, 1.18-1.75; $p < 0.001$). In Model 3, which was further adjusted for comorbidities and medication use, the result did not change substantially (HR 1.31, 95% CI: 1.08-1.61, $p = 0.007$) (Table 2). In the analysis by pharmacological class, anticoagulant use demonstrated a significantly increased risk (HR = 1.37, 95% CI: 1.01-1.86, $p = 0.040$). Specifically, warfarin showed a trend toward an increased risk, although it did not reach statistical significance (HR = 1.32, 95% CI: 0.97-1.80, $p = 0.076$). Analysis for other anticoagulants could not be performed or yielded imprecise results due to limitations in sample size. The overall association for antiplatelet agents was at the margin of statistical significance (HR = 1.27, 95% CI: 0.98-1.64, $p = 0.071$). The use of clopidogrel was associated with a significantly increased risk (HR = 1.53, 95% CI: 1.08-2.16, $p = 0.016$), whereas neither aspirin (HR =

1.02) nor dipyridamole (HR = 0.95) showed a significant association (Figure 2).

Subgroup Analysis

The analysis revealed significant interactions: the association between overall antithrombotic drug use and nonbiliary acute pancreatitis risk varied depending on the presence of diabetes (interaction P-value = 0.001) or hyperlipidemia (interaction P-value = 0.044). Specifically, among the non-diabetic population, antithrombotic drug use was significantly associated with an increased risk of nonbiliary acute pancreatitis (HR=1.52, 95% CI: 1.19-1.96, P=0.001). However, this association was not observed in the diabetic population (HR = 1.08, 95% CI: 0.78-1.50, P = 0.644). The risk increase was more pronounced in the non-hyperlipidemic population (HR=1.96, 95% CI: 1.22-3.15, P=0.006), while the association was weaker and did not reach statistical significance in the hyperlipidemic population (HR=1.23, 95% CI: 0.99-1.53, P=0.063) (Figure 3).

Stratified by drug class, we further evaluated the effect modification by diabetes and hyperlipidemia. A significant interaction with diabetes was observed among anticoagulant users (P for interaction = 0.019). Given that warfarin was the predominant anticoagulant in this study (other anticoagulants were not analyzed due to insufficient sample size), a subgroup analysis focusing on warfarin confirmed that this interaction remained statistically significant (P for interaction = 0.015). Specifically, among participants without diabetes, conventional warfarin use was associated with a 64% increased risk of

acute pancreatitis (HR = 1.64, 95% CI: 1.15-2.35), whereas no statistically significant association was observed in participants with diabetes. Furthermore, hyperlipidemia did not show a significant effect-modifying effect on anticoagulants. Among users of antiplatelet agents (including low-dose aspirin, clopidogrel, and dipyridamole), no significant interactions with either diabetes or hyperlipidemia were found (Supplementary Table 3).

Sensitivity Analysis

The association remained stable after further adjustment for history of cardiovascular disease (HR = 1.31, 95% CI: 1.08-1.61). After excluding nonbiliary acute pancreatitis cases that occurred within the first year of follow-up, the association remained statistically significant (HR = 1.25, 95% CI: 1.01-1.54; Supplementary Table 4). In a sensitivity analysis using a propensity score-matched cohort of 55,694 participants (Supplementary Table 5), regular antithrombotic drug use was associated with a 37% increased risk (HR = 1.37, 95% CI: 1.01-1.86).

Discussion

In this prospective cohort study, we found that regular antithrombotic drug use was associated with a 31% increased risk of nonbiliary acute pancreatitis after adjusting for potential confounding factors. In-depth analysis revealed significant heterogeneity in this risk: the increased risk was primarily concentrated in anticoagulants (HR=1.37) and

clopidogrel (HR=1.53), while warfarin showed only a trend toward increased risk, and aspirin and dipyridamole did not demonstrate significant risk. From a comorbidities perspective , diabetes and hyperlipidemia significantly modified the overall risk (interaction P-values: 0.047 and 0.032), with increased risk predominantly observed in non-diabetic and non-hyperlipidemic individuals. Further pharmacologic stratification revealed selective modification: Diabetes significantly modified the risk association with anticoagulants (including warfarin), again predominantly in non-diabetic individuals, whereas hyperlipidemia showed no significant modification with anticoagulants. No significant effect modification was observed for either condition with antiplatelet agents. These findings suggest that patients prescribed anticoagulants or clopidogrel, particularly those without diabetes, should be monitored for potential symptoms of pancreatitis.

To the best of our knowledge, this is the first prospective cohort study to investigate the association between the use of antithrombotic drugs and nonbiliary acute pancreatitis. Although previous research has extensively studied the association between the use of antithrombotic drugs and cardiovascular diseases[18,19], cerebrovascular disease[20,21], and risk of liver injury[22,23], their potential pancreatotoxicity has received limited attention. Notably, some animal studies suggest that pretreatment with agents like low doses of warfarin may attenuate pancreatic injury in experimental models[10,11]. However, these experimental findings appear to contradict the results of our present study, which provides the first large-scale epidemiological evidence indicating an increased risk

of nonbiliary acute pancreatitis associated with antithrombotic drug use in humans, with clopidogrel being a primary contributor. Moreover, we found that diabetes mellitus significantly modifies the association between warfarin and nonbiliary acute pancreatitis, and these findings provide important evidence for personalized risk assessment in clinical practice.

Our study proposes a potential mechanism explaining the increased risk of nonbiliary acute pancreatitis associated with clopidogrel. Clopidogrel, as a P2Y12 receptor antagonist, might contribute to pancreatic injury by affecting P2Y12 receptors on pericytes in the pancreatic microcirculation. Recent studies have shown that P2Y12 receptors are also expressed on vascular smooth muscle cells (VSMCs), where their activation inhibits the cAMP/protein kinase A pathway[24]. This inhibition effect leads to dephosphorylation of the cytoskeletal regulator Cofilin, promoting actin depolymerization and enhanced cell motility[25,26] . Given the high degree of homology between VSMCs and pericytes, and the established expression of P2RY12 receptors in pericytes[27], pancreatic pericytes likely also express functional P2Y12 receptors. Signals transmitted through these receptors regulate cytoskeletal proteins such as actin-depolymerizing factors, thereby maintaining pericyte adhesion capacity and cytoskeletal plasticity. Clopidogrel antagonism disrupts this regulation, reducing cytoskeletal remodeling and increasing pericyte rigidity. This disruption effect compromises their capillary support function and connections with endothelial cells,

thereby impairing the integrity of the microvascular barrier. The consequent increase in vascular permeability promotes the extravasation of inflammatory mediators and leukocyte infiltration, ultimately triggering or exacerbating local pancreatic inflammation[28,29]. In contrast, aspirin inhibits thromboxane A2 synthesis by acetylating platelet COX-1, an action highly restricted to platelets[30]. Dipyridamole enhances intracellular cAMP levels by inhibiting phosphodiesterase, thereby suppressing platelet activation and promoting vasodilation; it also potentiates these effects by elevating adenosine levels[31]. Since neither drug directly interferes with the P2Y12 receptor signaling pathway, no significant association with acute pancreatitis risk has been observed for either.

Further analysis revealed that anticoagulant use was associated with a significantly increased risk of nonbiliary acute pancreatitis (HR=1.37). Although the risk estimate for warfarin—the most widely used agent in this class—did not reach statistical significance in monotherapy analysis, its risk trend was consistent with the overall class effect, suggesting that a true association might have been obscured by insufficient statistical power in the subgroup analysis. Two possible explanations exist. First, the overall risk signal may be primarily driven by direct oral anticoagulants (DOACs), which could not be analyzed due to sample size limitations. A previous study has reported its association with pancreatitis risk[32]. Second, as a vitamin K antagonist, warfarin inhibits the synthesis of multiple vitamin K-dependent proteins, including matrix Gla protein (MGP).

MGP is a key factor in maintaining vascular homeostasis and suppressing calcification[33,34]. Warfarin may impair pancreatic microvascular function by inducing vascular calcification through MGP inhibition, ultimately increasing pancreatic tissue susceptibility to inflammation. Further analysis revealed that both diabetes and hyperlipidemia showed significant effect modification at the overall level. However, in drug-specific analyses, only diabetes confirmed a risk-modifying effect on warfarin (interaction p=0.015). The signal for hyperlipidemia in the overall analysis may stem from its interaction with other unanalyzed antithrombotic drugs or remain undetectable due to insufficient statistical power after sample splitting. Regarding warfarin risk being primarily concentrated in non-diabetic individuals, we propose the following explanation: diabetic status often coexists with a hypercoagulable state, which itself constitutes a risk factor for pancreatic microcirculatory dysfunction and acute pancreatitis[35–37]. In this context, warfarin's anticoagulant effect may partially improve pancreatic microcirculation, thereby offsetting its potential risk via the MGP pathway. Conversely, in non-diabetic individuals with normal coagulation function, warfarin's direct injury mechanism predominates. Furthermore, the extremely high baseline risk of pancreatitis in diabetic patients may partially mask the additional relative risk posed by warfarin[38]. In summary, this study demonstrates that the pancreatitis risk associated with anticoagulants (particularly warfarin) is not uniformly distributed but is significantly modified by the patient's diabetic status. This finding underscores the necessity of comprehensively considering the patient's specific metabolic pathology when assessing the safety of drugs

like warfarin.

Our study has several strengths, including its prospective design, large sample size, and extended follow-up period. We utilized propensity score matching to enhance intergroup comparability. Notably, our subgroup analyses systematically identified, for the first time, that diabetes status is a significant effect modifier of the warfarin-AP association. The most critical finding—that the risk was elevated primarily in low-risk individuals (e.g., those without diabetes)—holds profound clinical implications. This counterintuitive pattern serves as a clear warning, underscoring the imperative of conducting a thorough benefit-risk assessment before initiating antithrombotic therapy, even in patients perceived to be at low baseline risk, to avoid underestimating potential treatment-related hazards.

However, several limitations exist. First, despite rigorous adjustment for known confounders using propensity score matching, residual confounding may persist due to the observational design. Second, analyses of specific antithrombotic drug subtypes, particularly those beyond anticoagulants and clopidogrel, may have been underpowered due to limited sample sizes. Consequently, while the data suggest potential risk heterogeneity, definitive conclusions for most subtypes cannot be drawn and require validation in larger studies. Third, outcome misclassification is possible due to reliance on medical coding. Finally, as the cohort was predominantly White (94.3%), the generalizability of our findings to other racial or ethnic groups may be limited,

necessitating future validation in more diverse populations.

Conclusions

This large prospective cohort study establishes that regular antithrombotic medication use—particularly with clopidogrel—is associated with an increased risk of nonbiliary acute pancreatitis. Furthermore, it identifies underlying metabolic status as a key modifier of this risk. Strikingly, diabetes status exerts a negative modifying effect on the warfarin-associated risk, which was more pronounced in individuals without diabetes. This counterintuitive finding underscores the necessity of personalized risk assessment in clinical decision-making for antithrombotic therapy, with particular vigilance warranted in seemingly “healthy” populations. Future research should prioritize elucidating the underlying biological mechanisms and validating these findings at the level of specific drug subtypes in additional high-quality cohorts.

Data availability statement

UK Biobank is an open-access resource, and the study website https://www.ukbiobank.ac.uk/ provides information on available data and access procedures. Data sets used for analysis will be made available upon reasonable request.

Ethics statement

Ethics approval for the UK Biobank was granted by the North West Multi-Centre Research Ethics Committee in 2006 and was updated regularly after that (https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/about-us/ethics). All participants provided informed written consent to take part in the study and be followed-up through linkage to health-related records. Concerning the sensitivity of genetic data, the UK Biobank strictly prohibits researchers from using any genetic or other data to identify participants. This would violate the legal agreement researchers signed when they were granted access to the UK Biobank data.

Author Contributions

CW: Writing - original draft, Visualization, Investigation, Data curation, Formal analysis, Conceptualization. NM: Writing - original draft, Methodology, Formal analysis. JZ: Investigation, Methodology, Formal analysis. PL: Validation, Methodology. ZA: Methodology. SC: Visualization, Investigation. YL: Writing - review & editing. PY: Writing - review & editing. JY: Writing - review & editing, Supervision, Formal analysis.

WM: Writing - review & editing, Supervision, Funding acquisition.

Funding

This work was supported by the Major Program of the Gansu Province Joint Scientific Research Fund (23JRRA1488); Major Scientific and Technological Innovation Project of Gansu Provincial Health Industry (GSWSQNPY2024-10); and the Lanzhou Talent Innovation and Entrepreneurship Project (2022-3-42).

Acknowledgements

We thank all participants and researchers from the UK Biobank who make the study possible.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

During the writing process of this work, the authors used DeepSeek-R1 in order to improve language only. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.

Reference

[1] Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol 2019;16:479–96. https://doi.org/10.1038/s41575-019-0158-2.

[2] Zerem E. Treatment of severe acute pancreatitis and its complications. World J Gastroenterol 2014;20:13879–92. https://doi.org/10.3748/wjg.v20.i38.13879.

[3] Han K, Chen S, Song Y, Du C, Gao F, Liu S, He Y, Chai N, Linghu E, Liu M. Burden of pancreatitis and associated risk factors in China, 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Chin Med J (Engl) 2022;135:1340–7. https://doi.org/10.1097/CM9.0000000000002164.

[4] van Geenen EJM, van der Peet DL, Bhagirath P, Mulder CJJ, Bruno MJ. Etiology and diagnosis of acute biliary pancreatitis. Nat Rev Gastroenterol Hepatol 2010;7:495–502. https://doi.org/10.1038/nrgastro.2010.114.

[5] Scherer J, Singh V, Pitchumoni CS, Yadav D. Issues in Hypertriglyceridemic Pancreatitis - An Update. J Clin Gastroenterol 2014;48:195–203. https://doi.org/10.1097/01.mcg.0000436438.60145.5a.

[6] Szatmary P, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, Beyer G, Sutton R. Acute Pancreatitis: Diagnosis and Treatment. Drugs 2022;82:1251–76. https://doi.org/10.1007/s40265-022-01766-4.

[7] **Xie H**, **Jiang L**, Peng J, Hu H, Han M, Zhao B. Drug-induced pancreatitis: a real-world analysis of the FDA Adverse Event Reporting System and network pharmacology. Front Pharmacol 2025;16:1564127.

https://doi.org/10.3389/fphar.2025.1564127.

[8] World Health Organization. The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. World Health Organization; 2025. https://doi.org/10.2471/B09474.

[9] Zhang W, Yu E, Zhao W, Wu C, Ji X. Secondary prevention for intracranial atherosclerotic stenosis: Where we stand and challenges ahead. J Transl Intern Med 2024;12:537–9. https://doi.org/10.1515/jtim-2024-0037.

[10] Maduzia D, Ceranowicz P, Cieszkowski J, Gałązka K, Kuśnierz-Cabala B, Warzecha Z. Pretreatment with Warfarin Attenuates the Development of Ischemia/Reperfusion-Induced Acute Pancreatitis in Rats. Mol Basel Switz 2020;25:2493. https://doi.org/10.3390/molecules25112493.

[11] Konarska-Bajda K, Ceranowicz P, Cieszkowski J, Ginter G, Stempniewicz A, Gałązka K, Kuśnierz-Cabala B, Dumnicka P, Bonior J, Warzecha Z. Administration of Warfarin Inhibits the Development of Cerulein-Induced Edematous Acute Pancreatitis in Rats. Biomolecules 2023;13:948. https://doi.org/10.3390/biom13060948.

[12] **Kim DH**, **Ko D**, Elizondo Alatorre C, Lukens FJ, Porres JA, Palacios Argueta P, Raimondo M, Ji B, Bi Y, Kröner PT. Low-dose aspirin use is associated with reduced 30- and 90-day mortality and overall improved outcomes in patients with acute pancreatitis: A multinational multicenter analysis. Pancreatology 2025;25:1080–5. https://doi.org/10.1016/j.pan.2025.09.022.

[13] Wilks AB, Douce D, Ades S, Cushman M, Zakai NA, Holmes CE. Bleeding Risk in a Cohort of Ambulatory Cancer Patients Receiving Outpatient Prophylactic Anticoagulation for Venous Thrombosis Prevention. Blood 2019;134:709. https://doi.org/10.1182/blood-2019-128831.

[14] Chilbert MR, Gressel L, Lee L, Kersten B, Zammit K, Woodruff AE. Use of Prophylactic or Therapeutic Anticoagulation in Critically Ill Patients With Pre-existing Atrial Fibrillation. Hosp Pharm 2025;60:232–8. https://doi.org/10.1177/00185787241295997.

[15] **Yin Y**, **Wang L**, Gao F, Liu L, Qi X. Anticoagulation Therapy for Splanchnic Vein Thrombosis Associated With Acute Pancreatitis: A Systematic Review and Meta-Analysis. Clin Appl Thromb Off J Int Acad Clin Appl Thromb 2023;29:10760296231188718. https://doi.org/10.1177/10760296231188718.

[16] Norton W, Lazaraviciute G, Ramsay G, Kreis I, Ahmed I, Bekheit M. Current practice of anticoagulant in the treatment of splanchnic vein thrombosis secondary to acute pancreatitis. Hepatobiliary Pancreat Dis Int HBPD INT 2020;19:116–21. https://doi.org/10.1016/j.hbpd.2019.12.007.

[17] Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12:e1001779. https://doi.org/10.1371/journal.pmed.1001779.

[18] Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, AFIRE Investigators. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med 2019;381:1103–13. https://doi.org/10.1056/NEJMoa1904143.

[19] Song PS, Park YH, Oh J-H, Song YB, Choi S-H, Gwon H-C, Cho D-K, Rha S-W, Bae J-W, Jeong J-O, Hahn J-Y, SMART-DATE and the SMART-CHOICE investigators. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials. Am J Cardiol 2021;150:47–54. https://doi.org/10.1016/j.amjcard.2021.03.053.

[20] Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC, CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–9. https://doi.org/10.1056/NEJMoa1215340.

[21] Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 2018;379:215–25. https://doi.org/10.1056/NEJMoa1800410.

[22] Alonso A, MacLehose RF, Chen LY, Bengtson LG, Chamberlain AM, Norby FL, Lutsey PL. Prospective study of oral anticoagulants and risk of liver injury in

patients with atrial fibrillation. Heart 2017;103:834–9. https://doi.org/10.1136/heartjnl-2016-310586.

[23] Björnsson HK, Gudmundsson DO, Björnsson ES. Liver injury caused by oral anticoagulants: A population-based retrospective cohort study. Liver Int Off J Int Assoc Study Liver 2020;40:1895–900. https://doi.org/10.1111/liv.14559.

[24] Wihlborg A-K, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, Erlinge D. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 2004;24:1810–5. https://doi.org/10.1161/01.ATV.0000142376.30582.ed.

[25] Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J 1998;336 (Pt 3):513–23. https://doi.org/10.1042/bj3360513.

[26] Pillois X, Chaulet H, Belloc I, Dupuch F, Desgranges C, Gadeau A-P. Nucleotide receptors involved in UTP-induced rat arterial smooth muscle cell migration. Circ Res 2002;90:678–81. https://doi.org/10.1161/01.res.0000013700.98464.8e.

[27] **Barnett SN**, **Cujba A-M**, **Yang L**, Maceiras AR, Li S, Kedlian VR, Pett JP, Polanski K, Miranda AMA, Xu C, Cranley J, Kanemaru K, Lee M, Mach L, Perera S, Tudor C, Joseph PD, Pritchard S, Toscano-Rivalta R, Tuong ZK, Bolt L, Petryszak R, Prete M, Cakir B, Huseynov A, Sarropoulos I, Chowdhury RA, Elmentaite R, Madissoon E, Oliver AJ, Campos L, Brazovskaja A, Gomes T, Treutlein B, Kim CN, Nowakowski TJ, Meyer KB, Randi AM, Noseda M, Teichmann SA. An organotypic atlas of human vascular cells. Nat Med

2024;30:3468–81. https://doi.org/10.1038/s41591-024-03376-x.

[28] Cuthbertson CM, Christophi C. Disturbances of the microcirculation in acute pancreatitis. Br J Surg 2006;93:518–30. https://doi.org/10.1002/bjs.5316.

[29] Menger MD, Plusczyk T, Vollmar B. Microcirculatory derangements in acute pancreatitis. J Hepatobiliary Pancreat Surg 2001;8:187–94. https://doi.org/10.1007/s005340170015.

[30] Patrono C. Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease. Eur Heart J 2024;45:2362–76. https://doi.org/10.1093/eurheartj/ehae324.

[31] Ali Hassan R, Patel P. Dipyridamole. StatPearls, Treasure Island (FL): StatPearls Publishing; 2025.

[32] Badalov N, Baradarian R, Iswara K, Li J, Steinberg W, Tenner S. Drug-Induced Acute Pancreatitis: An Evidence-Based Review. Clin Gastroenterol Hepatol 2007;5:648-661.e3. https://doi.org/10.1016/j.cgh.2006.11.023.

[33] Danziger J. Vitamin K-dependent Proteins, Warfarin, and Vascular Calcification. Clin J Am Soc Nephrol CJASN 2008;3:1504–10. https://doi.org/10.2215/CJN.00770208.

[34] Willems BAG, Vermeer C, Reutelingsperger CPM, Schurgers LJ. The realm of vitamin K dependent proteins: Shifting from coagulation toward calcification. Mol Nutr Food Res 2014;58:1620–35. https://doi.org/10.1002/mnfr.201300743.

[35] Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44–54. https://doi.org/10.1016/s1056-8727(00)00132-x.

[36] Chung KH, Cho IR, Choi YH, Cho YD, Ryu JK, Lee SH, Han K. Association between diabetic status and risk of acute pancreatitis: A nationwide population-based study. J Evid-Based Med 2024;17:588–96. https://doi.org/10.1111/jebm.12637.

[37] Yang L, He Z, Tang X, Liu J. Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2013;25:225–31. https://doi.org/10.1097/MEG.0b013e32835af154.

[38] Urushihara H, Taketsuna M, Liu Y, Oda E, Nakamura M, Nishiuma S, Maeda R. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PloS One 2012;7:e53224. https://doi.org/10.1371/journal.pone.0053224.

Author names in bold designate shared co-first authorship

Figure legends

Figure 1. Cumulative Incidence of Nonbiliary Acute Pancreatitis Among Users of Antithrombotic Drugs, Antiplatelet or Anticoagulant Drugs, and Specific Agents Compared with Non-Users.

Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake, multivitamin use and intake of mineral supplements. **Figure 1a** shows the cumulative incidence of nonbiliary acute pancreatitis in overall antithrombotic drug users and non-users. **Figure 1b** shows the cumulative incidence of nonbiliary acute pancreatitis in antiplatelet drug users, anticoagulant drug users, and non-users. **Figure 1c** shows the cumulative incidence of nonbiliary acute pancreatitis in clopidogrel, warfarin, aspirin, dipyridamole users, and non-users. IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug; nonbiliary acute pancreatitis, non-gallstone acute pancreatitis**.**

Figure 2. Association of Antithrombotic Drug Use with Nonbiliary Acute Pancreatitis: An Analysis of Overall, Stratified, and Individual Medication Effects.

Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary

characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake, multivitamin use and intake of mineral supplements. IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug**.**

Figure 3. Subgroup analyses of Antithrombotic use and the risk of Nonbiliary Acute Pancreatitis.

Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake, multivitamin use and intake of mineral supplements. IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug**.**

Table 1. Baseline characteristics of participants by antithrombotic use in the UK Biobank

Characteristics	Antithrombotic use		Overall
	No（N=420,614）	**Yes (N=11,140)**	
Number of participants	(N=420614)	(N=11140)	(N=431754)
Anticoagulant only	/	4,452	/
Warfarin	/	4,397	/
Antiplatelet only	/	6,610	/
Low-dose Aspirin	/	2,514	/
Dipyridamole	/	950	/
Clopidogrel	/	2,818	/
Aspirin and Clopidogrel	/	93	/
Anticoagulant and Antiplatelet	/	78	/
Mean (SD)age	56.2 (8.10)	61.7 (6.26)	56.3 (8.11)
Male	195105 (46.4%)	7799 (70.0%)	202904 (47.0%)
White	396396 (94.2%)	10502 (94.3%)	406898 (94.2%)
Mean (SD) Index of Multiple Deprivation	17.2 (13.8)	19.4 (15.3)	17.2 (13.8)
Mean (SD)BMI	27.3 (4.71)	29.2 (5.18)	27.4 (4.73)
Smoking	187613 (44.6%)	6454 (57.9%)	194067 (44.9%)
Drinking	/	/	/
Never	79126 (18.8%)	2810 (25.2%)	81936 (19.0%)
Low	46553 (11.1%)	1104 (9.9%)	47657 (11.0%)
Moderate	207958 (49.4%)	4751 (42.6%)	212709 (49.3%)
High	86632 (20.6%)	2461 (22.1%)	89093 (20.6%)
Physical activity	/	/	/
High	135361 (32.2%)	3047 (27.4%)	138408 (32.1%)

Low	59600 (14.2%)	1929 (17.3%)	61529 (14.3%)
Moderate	132826 (31.6%)	3379 (30.3%)	136205 (31.5%)
HealthyDiet	212118 (50.4%)	5768 (51.8%)	217886 (50.5%)
NASIDS	69906 (16.6%)	699 (6.3%)	70605 (16.4%)
Hypolipidemic drug	71717 (17.1%)	8142 (73.1%)	79859 (18.5%)
Vitamin	63113 (15.0%)	1636 (14.7%)	64749 (15.0%)
Mineral	91240 (21.7%)	1596 (14.3%)	92836 (21.5%)
Diabetes	34044 (8.1%)	3028 (27.2%)	37072 (8.6%)
Hypertension	305680 (72.7%)	9819 (88.1%)	315499 (73.1%)
Hyperlipidemia	201352 (47.9%)	9363 (84.0%)	210715 (48.8%)
Myocardial Infarction	16671 (4.0%)	439 (3.9%)	17110 (4.0%)
Coronary Heart Disease	22737 (5.4%)	599 (5.4%)	23336 (5.4%)
Myocardial Infarction	4624 (1.1%)	136 (1.2%)	4760 (1.1%)
Peripheral Vascular Disease	6987 (1.7%)	188 (1.7%)	7175 (1.7%)
Stroke	6638 (1.6%)	187 (1.7%)	6825 (1.6%)

Abbreviations: SD, standard deviation; BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs;

Values are numbers (percentages) unless stated otherwise.

Table 2. Associations between Antithrombotic use and risk of Nonbiliary Acute Pancreatitis(n=431,754).

Variables	**Antithrombotic use**		**p-value**
	No （N=420,614）	**Yes (N=11,140)**	
Case/person-years	2,080 / 5,652,141	109 / 139,161	
IR (per 10,000 person-years)	3.68	7.83	
Multivariate-adjusted HR (95% CI)			
Crude model	1.00 (Reference)	1.74（1.44-2.12）	<0.001

model 1	1.00 (Reference)	1.66 (1.37-2.02)	<0.001
model 2	1.00 (Reference)	1.44 (1.18-1.75)	<0.001
model 3	1.00 (Reference)	1.31 (1.08-1.61)	0.007

Crude model: Unadjusted for covariates in the crude model;Model 1 adjusted for age, gender, ethnicity, and Index of Multiple Deprivation (IMD);Model 2 additionally adjusted for BMI, smoking status, alcohol intake, physical activity, and dietary characteristics; Model 3 further adjusted for comorbidities and medication use on the basis of Model 2, including type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, hypolipidemic drugs, multivitamins, and mineral supplements.

Abbreviations: IR, incidence rate; HR, hazard ratio; CI, confidence interval; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

Figure 1. All adjusted HRs were adjusted for the following covariates: age, gender,

ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, Hypolipidemic drug intake, multivitamin use and intake of mineral supplements.

Abbreviations: HR, hazard ratio; CI, confidence interval; IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.




Drug Categories
b
Antiplatelet: HR 1.27 (95%CI 0.98−1.64)
Anticoagulant: HR 1.37 (95%CI 1.01−1.86)
Non−users: Reference
Cumulative Incidence of Nonbiliary Acute Pancreatitis(%)
1.50
1.00
0.50
0.00
0
2.5
5
7.5
10
12.5
15
Number at risk
6610 6495 6335 6094 5797 5215 326
4452 4330 4167 3958 3708 3237 222
420614 418449 414654 409257 402365 374892 31804
Time to event (Years)

643


Specific Antithrombotic Drugs
c
Clopidogrel: HR 1.53 (95%CI 1.08-2.16)
Warfarin: HR 1.32 (95%CI 0.97-1.80)
Aspirin: HR 1.02 (95%CI 0.65-1.61)
Dipyridamole: HR 0.95 (95%CI 0.45-2.00)
Non-users: Reference
Cumulative Incidence of Nonbiliary Acute Pancreatitis(%)
1.50
1.00
0.50
0.00
0
2.5
5
7.5
10
12.5
15
Number at risk
2818 2765 2687 2572 2431 2146 153
4397 4277 4117 3911 3663 3197 219
2514 2487 2439 2379 2291 2132 128
950 931 902 854 802 695 32
420614 418449 414654 409257 402365 374892 31804
0
2.5
5.0
7.5
10
12.5
15
Time to event (Years)

644

Figure 2. The model was adjusted for age, gender, ethnicity, the Index of Multiple Deprivation (IMD), BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, hyperlipidemia, NSAID intake, hypolipidemic drug intake, multivitamin use, and mineral supplement intake;

Abbreviations: BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.



Figure 3. Estimated effects were calculated using the Cox model adjusted by age, gender, ethnicity, IMD, BMI, smoking status, alcohol intake, physical activity, dietary characteristics, type 2 diabetes, hypertension, Hyperlipidemia, NSAID intake, multivitamin use, Hypolipidemic drug intake and intake of mineral supplements; Abbreviations: HR, hazard ratio; CI, confidence interval; IMD, index of multiple deprivation; BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug.

Subgroup	non-antithrombotic use		antithrombotic use		Multivariate-adjusted HR(95% CI)	P Value	P for Interaction
	case	person-years	case	person-years			
Age							0.910
(35,55]	709	2525127	13	22793	1.19 (0.68-2.09)	0.546	
(55,65]	947	2390321	54	73533	1.28 (0.96-1.70)	0.088	
(65,75]	424	736694	42	42836	1.40 (1.00-1.94)	0.047	
Gender							0.889
Female	1020	3054433	32	42929	1.33 (0.93-1.92)	0.118	
Male	1060	2597708	77	96233	1.30 (1.02-1.66)	0.031	
BMI							
less than 25kg/m2	426	1880600	19	26497	1.71 (1.05-2.77)	0.03	
25-30 kg/m2	870	2428087	34	61463	1.14 (0.80-1.62)	0.479	
at least 30 kg/m2	777	1315281	56	50872	1.36 (1.03-1.80)	0.033	
Smoking							0.741
Yes	1101	2494024	69	78884	1.28 (0.99-1.65)	0.055	
No	968	3138831	40	59393	1.41 (1.02-1.96)	0.038	
Drinking							0.544
Never	526	1051145	33	34437	1.32 (0.91-1.90)	0.138	
Low	233	627878	8	13875	1.03 (0.50-2.12)	0.946	
Moderate	907	2809485	48	59700	1.47 (1.09-1.99)	0.012	
High	409	1159129	20	30975	1.19 (0.75-1.89)	0.464	
Physical Activity							0.650
Low	935	2856079	51	72992	1.55(1.02-2.33)	0.038	
Moderate	1145	2796062	58	66169	1.52(1.05-2.20)	0.027	
High	562	1823065	21	39167	1.00(0.64-1.57)	0.99	
Diet							0.968
Healthy	341	798247	27	23389	1.27 (0.95-1.70)	0.112	
Unhealthy	611	1789408	32	42241	1.36 (1.03-1.79)	0.028	
Hyperlipidemia							0.044
Yes	1301	2684075	91	116556	1.23 (0.99-1.53)	0.644	
No	779	2968066	18	22605	1.96 (1.22-3.15)	0.001	
Diabetes							0.010
Yes	461	440728	40	36479	1.08 (0.78-1.50)	0.015	
No	1619	5211413	69	102682	1.52 (1.19-1.96)	0.179	
Hypertension							0.614
Yes	1670	4087924	98	122365	1.30 (1.05-1.61)	0.063	
No	407	1559938	11	16782	1.54 (0.82-2.87)	0.006	
NSAIDs							0.676
Yes	360	942313	7	8732	1.19 (0.55-2.56)	0.659	
No	1720	4709828	102	130429	1.32 (1.07-1.62)	0.009	
Hypolipidemic drug							0.361
yes	539	934428	81	100727	1.40 (0.87-2.25)	0.162	
no	1541	4717713	28	38434	1.23 (0.99-1.53)	0.057	
Vitamin							0.583
Yes	328	844741	19	20443	1.43 (0.88-2.32)	0.144	
No	1752	4807400	90	118718	1.28 (1.03-1.60)	0.027	
Mineral							0.867
Yes	415	1229229	14	20387	1.20 (0.69-2.08)	0.514	
No	1665	4422912	95	118774	1.33 (1.07-1.65)	0.009